A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer.

Margaret E Gatti-MaysFatima H KarzaiSanaz N SoltaniAlexandra ZimmerJeffrey E GreenMin-Jung LeeJane B TrepelAkira YunoStanley LipkowitzJayakumar NairAnn McCoyJung-Min Lee

Published in: The oncologist (2020)

Prexasertib monotherapy had modest clinical efficacy in BRCAwt TNBC. Further studies of prexasertib in combination with other agents are needed.

Keyphrases

phase ii
wild type
open label
clinical trial
phase iii
placebo controlled
double blind
randomized controlled trial
case control
dna damage response
study protocol